Rani Therapeutics, a San Jose CA-based developer of a novel approach for the oral delivery of large drug molecules, closed a Series C round of funding of undisclosed amount.
Participants included Novartis, Google Ventures, InCube Ventures, VentureHealth, The Stevanato Group, Crystal Horizon Investments, Pinemount Investments, Pacific Venture Opportunity Fund, and Buttonwood Funds.
The company intends to use the funds to continue to de-risk the platform and create the manufacturing infrastructure they need for clinical trials and beyond.
Led by Mir Imran, Chairman & CEO, Rani Therapeutics Rani Therapeutics has developed a novel approach for the oral delivery of peptides, proteins and therapeutic antibodies.
The company recently announced a collaboration partnership with Novartis, including feasibility studies to evaluate how selected Novartis proprietary biologics can be delivered into the bloodstream using Rani’s route of administration.